Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Johnson & Johnson (NY:JNJ)

199.58 +3.65 (+1.86%)
Official Closing Price Updated: 7:00 PM EST, Nov 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Johnson & Johnson

< Previous 1 2
...
27 28 29 30 31 32 33 34 35
...
99 100 Next >
News headline image
These Are the 5 Worst-Performing Stocks in the Dow Jones Industrial Average With 2024 Almost Over ↗
Via The Motley Fool
Topics Stocks
News headline image
Jim Cramer Says This CEO 'Built An Amazing Company,' Recommends Buying Netflix ↗
When asked about Advanced Micro Devices, Cramer asks: "But can we just remember Lisa Su has built an amazing company?" 
Via Benzinga
News headline image
Jim Cramer Bullish On Netflix Nearing $1,000 And AMD's 'Cheap' Valuation Despite Nvidia Dominance ↗
Jim Cramer expressed strong buying conviction for Netflix Inc. during Wednesday's Lightning Round on "Mad Money," as the streaming giant's shares traded near $934 amid broader tech market strength. 
Via Benzinga
News headline image
Elon Musk's Net Worth Surpasses Market Cap Of US Giants Like BofA, Johnson & Johnson, Salesforce, Chevron, Coca-Cola And More: Only 25 Companies Have Higher Market Cap ↗
Only 25 listed companies have a higher market capitalization than Elon Musk's skyrocketing net worth. 
Via Benzinga
News headline image
The Analyst Landscape: 15 Takes On Johnson & Johnson ↗
 
Via Benzinga
News headline image
Why NYSE:JNJ is a Top Pick for Dividend Investors. ↗
Exploring JOHNSON & JOHNSON (NYSE:JNJ)'s dividend characteristics. 
Via Chartmill
News headline image
Spotlight on Johnson & Johnson: Analyzing the Surge in Options Activity ↗
 
Via Benzinga
News headline image
GSK's Blood Cancer Drug Shows Improved Survival Compared To Johnson & Johnson's Darzalex ↗
GSK's Blenrep combo demonstrates significant survival benefits and improved efficacy in relapsed multiple myeloma compared to Darzalex combo. 
Via Benzinga
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
Johnson & Johnson to Host Investor Conference Call on Fourth-Quarter Results
From Johnson & Johnson
Via Business Wire
News headline image
Arcellx And Legend Bio Trade Jabs In Multiple Myeloma. But Only One Pulls Ahead. ↗
The companies held competing events on Sunday to discuss their multiple myeloma treatments. 
Via Investor's Business Daily
News headline image
Price Over Earnings Overview: Johnson & Johnson ↗
 
Via Benzinga
News headline image
This Is What Whales Are Betting On Johnson & Johnson ↗
 
Via Benzinga
News headline image
Coca-Cola cs. Procter & Gamble: Which Is the Better Dow Dividend King Stock to Buy Before the End of the Year? ↗
Via The Motley Fool
Topics Stocks
News headline image
Top Analyst Reports For Home Depot, Johnson & Johnson & Salesforce ↗
Today's Research Daily features new research reports on 16 major stocks, including The Home Depot, Inc., Johnson & Johnson, and Salesforce, Inc., as well as two micro-cap stocks, Preformed Line... 
Via Talk Markets
Topics Stocks / Equities
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
Celebrating innovation happens from the inside out
(BPT) - For more than a century, Johnson & Johnson has been synonymous with innovation in science and medicine by moving the needle in building a world where complex diseases are prevented and cured,... 
Via Brandpoint
News headline image
Ray Dalio's Bridgewater Adds Broadcom, Apple, SMCI In Q3, While Offloading Stake In AI Giant Nvidia And Other Big Tech Companies ↗
Bridgewater Associates, the world's biggest hedge fund, sold top AI-linked stocks like Nvidia, Alphabet, Microsoft, Amazon, and Johnson & Johnson. 
Via Benzinga
Topics Artificial Intelligence
News headline image
3 Fantastic Dividend Stocks to Buy Sooner Rather Than Later ↗
Via The Motley Fool
News headline image
Bristol-Myers Squibb Files Lawsuit Against US Agency For Overreach In 340B Drug Pricing Program ↗
Bristol Myers Squibb sues HRSA, claiming its rejection of a rebate model for 340B pricing violates federal law. The lawsuit highlights concerns over program abuse and regulatory overreach. 
Via Benzinga
Topics Lawsuit
News headline image
2 Very Healthy Dividend Stocks to Hold for Decades of Income ↗
Via The Motley Fool
News headline image
3 Dividend Stocks That Are Screaming Buys in November ↗
Political uncertainty has created buying opportunities among blue-chip healthcare stocks with big-time dividends. 
Via The Motley Fool
News headline image
2 Unstoppable Dividend Stocks to Buy Now With $500 ↗
Via The Motley Fool
News headline image
2 Dow Jones Dividend Stocks With Yields Above 3% You Can Buy Now and Hold at Least a Decade ↗
Via The Motley Fool
Topics Stocks
News headline image
ORIC: Working with Two Pharma Giants, Analysts See +100% Upside
ORIC Pharmaceuticals is a stock analyst price targets currently signal double-bagger potential in. See what the excitement around this firm is all about. 
Via MarketBeat
News headline image
This Johnson & Johnson Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday ↗
 
Via Benzinga
News headline image
Trump Taps RFK Jr. For Health Secretary Role, Sends 5 Vaccine Stocks Lower ↗
Trump may appoint Robert F. Kennedy Jr. as HHS Secretary, stirring mixed reactions. Kennedy's views on vaccines could reshape policies and affect vaccine stocks. 
Via Benzinga
Topics Government
News headline image
Cidara Therapeutics' Unique Cloudbreak Platform And Its Promise In Influenza And Oncology ↗
CDTX sold its Rezayo business to concentrate on its MDC-producing Cloudbreak platform which has already produced several promising drug candidates, like CD388, a very promising clinical-stage... 
Via Talk Markets
News headline image
Why Are These 3 Vanguard ETFs Underperforming the S&P 500 Since Election Day? ↗
Stocks in these "safe" sectors are selling off as investors gravitate toward growth. 
Via The Motley Fool
Topics ETFs Stocks
News headline image
Johnson & Johnson Challenges Government Drug Pricing Dispute Over Two Drugs ↗
Johnson & Johnson sues the U.S. government agency over a 340B Drug Pricing Program dispute, arguing the program's misuse. 
Via Benzinga
Topics Lawsuit
< Previous 1 2
...
27 28 29 30 31 32 33 34 35
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.